NuCana is an oncology focused Biopharma company dedicated to the development and commercialization of new medicines to treat patients with cancer. The ProTide Technology Platform has the potential to transform chemotherapy to targeted therapy. ProTides have been designed to target specific patient populations for whom existing chemotherapy is not likely to be effective. By overcoming the key resistance pathways, ProTides aim to significantly improve the efficacy, broaden the clinical utility, and improve the safety profile of many established anticancer agents.
Monique Saulnier is a Managing Partner and the COO of Sofinnova Partners. She joined in 1983 to initially follow US funds. She became Chief Financial Officer of Sofinnova Partners in 1997. She has 37 years of experience in the management of support team responsibilities for private equity.